Exubera U.S. Regulatory Update Coming Soon, Pfizer Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Pfizer believes it soon will be in a position to provide a regulatory update on the status of inhaled insulin. Company cites its Exubera partnership with Sanofi-Aventis and Nektar as an example of successful collaboration, although questions about the “change-of-control” provision with Sanofi-Aventis remain.
You may also be interested in...
Exubera Inhaled Insulin User Fee Deadline Is January 2006
Pfizer and Sanofi-Aventis filed the Exubera NDA March 1; an early 2006 approval is based on a standard 10-month review. The companies expected to submit an NDA in 2001, but were delayed by pulmonary safety questions.
Exubera Inhaled Insulin User Fee Deadline Is January 2006
Pfizer and Sanofi-Aventis filed the Exubera NDA March 1; an early 2006 approval is based on a standard 10-month review. The companies expected to submit an NDA in 2001, but were delayed by pulmonary safety questions.
Exubera Negotiations With Sanofi-Aventis Are Progressing Well, Pfizer Says
Negotiations with Sanofi-Aventis over the inhaled insulin Exubera are progressing along Pfizer's preferred track, CEO Hank McKinnell said